Mead Johnson Nutrition (NYSE: MJN) reported earnings on Oct. 25. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Sep. 30 (Q3), Mead Johnson Nutrition missed estimates on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue dropped slightly and GAAP earnings per share shrank.

Margins dropped across the board.

Revenue details
 Mead Johnson Nutrition reported revenue of $921.3 million. The 12 analysts polled by S&P Capital IQ looked for revenue of $976.9 million on the same basis. GAAP reported sales were 1.3% lower than the prior-year quarter's $933.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.71. The 15 earnings estimates compiled by S&P Capital IQ anticipated $0.72 per share. GAAP EPS of $0.69 for Q3 were 1.4% lower than the prior-year quarter's $0.70 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 61.2%, 40 basis points worse than the prior-year quarter. Operating margin was 20.9%, 210 basis points worse than the prior-year quarter. Net margin was 15.2%, 30 basis points worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $987.5 million. On the bottom line, the average EPS estimate is $0.72.

Next year's average estimate for revenue is $3.97 billion. The average EPS estimate is $3.10.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 77 members out of 91 rating the stock outperform, and 14 members rating it underperform. Among 27 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 21 give Mead Johnson Nutrition a green thumbs-up, and six give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Mead Johnson Nutrition is outperform, with an average price target of $80.36.